Takeda Pharmaceutical Co. has extended its lease in Cambridge’s Kendall Square through 2040. The Japanese drug giant, based in Tokyo, has its global US hub in Cambridge. It has signed on for a 10-year term for 223,000 square feet at 75/125 Binney St., a lab complex developed by Alexandria Real Estate Equities. The company is also planning to occupy a 16-story office and lab building at 585 Third St. nearby, a BioMed Realty project that’s under construction now and is slated to open next year. The lease extension comes at a time when many biotech companies have drawn down their lease requirements, though the Cambridge market has fared better than its surrounding neighbors. Lab availability is than 14 percent in Cambridge, compared to more than 18 percent in the suburbs and 19 percent in Boston.— CATHERINE CARLOCK